Related Experiment Videos
Long-term application of vindesine: toxicity and tolerance
W Rhomberg1, H Eiter, E Soltesz
1Department of Radiooncology, Landeskrankenhaus, Feldkirch, Austria.
Journal of Cancer Research and Clinical Oncology
|January 1, 1990
Summary
Vindesine shows no major long-term toxicity in patients treated continuously for up to seven years. Caution is advised when combining vindesine with high-dose radiation, particularly affecting the lungs.
Area of Science:
- Oncology
- Pharmacology
- Clinical Medicine
Background:
- Vindesine is a vinca alkaloid used in cancer chemotherapy.
- Long-term toxicity data for continuous vindesine administration is limited.
- Understanding the safety profile of vindesine is crucial for its clinical application.
Purpose of the Study:
- To evaluate the long-term toxicity of continuous vindesine administration in cancer patients.
- To assess the safety of vindesine in adjuvant and antimetastatic treatment settings.
- To identify potential risks associated with combined vindesine and radiation therapy.
Main Methods:
- Retrospective analysis of 14 patients receiving continuous vindesine therapy.
- Data collection on treatment duration, total dosage, and observed toxicities.
- Assessment of acute, subacute, and long-term adverse effects.
- Evaluation of drug interactions, specifically with radiation therapy.
Main Results:
- All patients experienced transient acute or subacute toxicities.
- No unequivocal signs of long-term or cumulative toxicity were observed.
- Concomitant use of higher radiation doses with vindesine led to more pronounced local reactions, especially in the lungs.
- Vindesine was tolerated over extended treatment periods (up to 7 years).
Conclusions:
- Continuous vindesine administration appears safe for extended periods with no major cumulative toxicity.
- Vindesine may be suitable for adjuvant therapy or antimetastatic strategies.
- Careful consideration is needed when combining vindesine with high-dose radiation due to increased local reactions.